The following slide deck was published by AtriCure, Inc.

AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin Group, Investor RelationsMichael Carrel -…

MASON, Ohio (AP) — MASON, Ohio (AP) — AtriCure Inc. (ATRC) on Tuesday reported a loss of $4.2 million in…

AtriCure press release (ATRC): Q4 GAAP EPS of -$0.09 beats by $0.09.Revenue of $88M (+20.2% Y/Y) beats by $0.1M.Adjusted EBITDA was positive for the fourth quarter 2022 at $6.0…

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2022 and full year 2022 financial results. “We delivered another outstanding year of growth in 2022, as we expanded adoption across our broad portfolio of solutions. I

AtriCure (NASDAQ: ATRC ) is set to give its latest quarterly earnings report on Tuesday, 2023-02-21. Here''s what investors need to know before the announcement. Analysts estimate that AtriCure will report an earnings per share (EPS) of $-0.18. AtriCure bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com

Trial will evaluate the safety and effectiveness of the AtriCure AtriClip Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients AtriCure, Inc. (Nasdaq: ATRC), a …

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was treated in the Left Atrial Appendage Exclusion for Stroke Prevention (LeAAPS™) clinical trial (NCT 05478304). The patient was treated by U.S. co-principal investigator Dr. Marc Gerdisch at Franciscan St. Francis Heart Center in Ind

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 21, 2023, to discuss its fourth quarter and full year 2022 financi